Cenobamate
- TRADE NAME: Xcopri (SK Life Science)
- INDICATIONS: Partial-onset seizures in adults.
- CLASS: Anticonvulsant, Antiepileptic, GABA A receptor positive modulator
- HALF-LIFE: 50–60 hours
FDA APPROVAL DATE: 11/21/2019
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, Clobazam, CYP2B6 substrates, CYP3A substrates, CYP2C19 substrates, Lamotrigine, Oral Contraceptives, Phenobarbital, Phenytoin
Based on animal data, may cause fetal harm. Women of reproductive potential concomitantly using oral contraceptives should use additional or alternative non-hormonal birth control.
Often used as an adjunctive therapy with other anticonvulsant (antiseizure) medication.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 03/07/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric